021-51111890
购物车（）
sales@molnova.cn
Cabozantinib
CAS No. 849217-68-1
Cabozantinib ( XL184;BMS-907351;XL-184;XL184 )
产品货号. M16165 CAS No. 849217-68-1
Cabozantinib (XL184, BMS-907351) is a potent multi-kinase inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥316 | 有现货 |
|
| 10MG | ￥446 | 有现货 |
|
| 50MG | ￥583 | 有现货 |
|
| 100MG | ￥786 | 有现货 |
|
| 200MG | ￥1256 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Cabozantinib
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Cabozantinib (XL184, BMS-907351) is a potent multi-kinase inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
-
产品描述Cabozantinib (XL184, BMS-907351) is a potent multi-kinase inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively; eliminates tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and tumor cell apoptosis, and slows regrowth of the tumor vasculature, also decreases invasiveness of primary tumors and reduces metastasis in pancreatic islet cancer; exerts marked anti-MPNST effects in vitro and in vivo.Kidney Cancer Approved
-
同义词XL184;BMS-907351;XL-184;XL184
-
通路Angiogenesis
-
靶点VEGFR
-
受体AXL;c-Met;Kit;VEGFR2/KDR;VEGFR3/FLT4;VEGFR2;MET;MET(Y1248H);RET;FLT3
-
研究领域Cancer
-
适应症Kidney Cancer
化学信息
-
CAS Number849217-68-1
-
分子量501.51
-
分子式C28H24FN3O5
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 30 mg/mL
-
SMILESCOC1=CC2=NC=CC(OC3=CC=C(C=C3)N(C(=O)C3(CC3)C(N)=O)C3=CC=C(F)C=C3)=C2C=C1OC
-
化学全称1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. You WK, et al. Cancer Res. 2011 Jul 15;71(14):4758-68.
2. Durante C, et al. Expert Opin Investig Drugs. 2011 Mar;20(3):407-413.
3. Torres KE, et al. Clin Cancer Res. 2011 Jun 15;17(12):3943-55.
4. Kurzrock R, et al. J Clin Oncol. 2011 Jul 1;29(19):2660-6.
2. Durante C, et al. Expert Opin Investig Drugs. 2011 Mar;20(3):407-413.
3. Torres KE, et al. Clin Cancer Res. 2011 Jun 15;17(12):3943-55.
4. Kurzrock R, et al. J Clin Oncol. 2011 Jul 1;29(19):2660-6.
产品手册
关联产品
-
Cabozantinib
Cabozantinib (XL184, BMS-907351) is a potent multi-kinase inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
-
Jaceidin
Jaceidin is a membrane-permeable inhibitor of VEGFR with anti-tumor activities.
-
Motesanib
A potent, orally bioavailable, multikinase inhibitor inhibitor of VEGFR1/2/3, PDGFR and c-Kit with IC50 of 2-6 nM, 84 nM and 8 nM, respectively.
